Newron completes Ph III safinamide enrollment

Newron Pharmaceuticals, an Italian company focused on novel central nervous system and pain therapies, says that patient enrollment has been completed in a Phase III clinical trial that will evaluate the efficacy and safety of safinamide, as add-on therapy to a stable dose of levodopa, for the treatment of patients with mid-to-late-stage Parkinson's disease. This study is one of the Phase III evaluations that constitute the clinical development program designed to support an application for marketing authorization as discussed with regulatory authorities.

"The completion of patient enrolment into this Phase III trial is another step forward with our clinical development program of safinamide," said Ravi Anand, chief medical officer of Newron. "It brings us closer to our objective of offering a new treatment option to patients with Parkinson's disease, a neurodegenerative disease with a high unmet medical need," he added.